All News
ICYMI: The Nine Lives of Hydroxychloroquine (Updated)
Hydroxychloroquine is one of many medications frequently used in rheumatology practice. Its remarkable versatility is attested by its routine use in lupus, in patients with an autoimmune coagulopathy, in patients with rheumatoid arthritis, as well as in those with a low-level inflammatory arthropathy.
Read Article
Hydroxychloroquine Improves Survival in Lupus
Hydroxychloroquine (HCQ) has dominated the news in recent weeks, because of poor outcomes reported when used in COVID patients. Yet, a recent report reaffirms what rheumatologists have known for years - that HCQ use is associated with better outcomes in systemic lupus erythematosus, including survival.
Read Article
Again, Antimalarial Use Fails to Benefit COVID
Today Lancet reported the results of another retrospective trial showing that hydroxychloroquine or chloroquine, alone or with a macrolide antibioitic, offered no additional benefits to COVID-19 patients, but was associated with higher rates of mortality and arrhythmia.
Read Article
The Nine Lives of Hydroxychloroquine (Updated)
Hydroxychloroquine is one of many medications frequently used in rheumatology practice. Its remarkable versatility is attested by its routine use in lupus, in patients with an autoimmune coagulopathy, in patients with rheumatoid arthritis, as well as in those with a low-level inflammatory arthropathy.
Read Article
RheumNow Podcast - Despite Corona (3.6.20)
Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com.
RheumNow Podcast - RWCS Quick Hits (2.14.20)
Dr. Jack Cush reviews the highlights from the 2020 RWCS meeting in Maui, Hawaii.
Read Article
Apremilast Reduces Oral Ulcers in Behcet's Syndrome
A multinational trial finds a statistically significant number of patients with Behçet's syndrome showed a greater reduction in the number of oral ulcers with apremilast compared with placebo.
Read Article
Hydroxychloroquine Blood Levels May Predict Future Retinopathy
A study of 527 patients receiving daily hydroxychloroquine (HCQ) concluded that hydroxychloroquine blood levels may predict future HCQ retinopathy.
Read Article
ACR 2018 - Day 1 Report
Highlights from Tuesday and Wednesday (days 3 and 4) from the ACR annual meeting include: the important and impactful abstracts covered by the Rheumatology Roundup session; upadacitinib clinical trials; and the baricitinib CV and VTE safety analysis.
Read Article
RheumNow Podcast – Believe in Vitamin D or Rituximab? (9.20.19)
Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com.
Read Article
Steroid Sparing Effects of Methotrexate and Mycophenolate in Uveitis
Patients with noninfectious uveitis (intermediate, posterior uveitis, or panuveitis) often require high dose corticosteroids and therefore may need steroid-sparing DMARD therapy. The FAST study investigated the corticosteroid-sparing effect of methotrexate or mycophenolate mofetil in adults with noninfectious uveitis.
Read Article
Blinded by the Use of Antimalarials in Lupus?
Editor's note: July 1 - 5, RheumNow is running the best of EULAR 2019 meeting. Hydroxychloroquine (HCQ) will decrease SLE flares improve lipids, decrease clots, improve survival, augment the response to mycophenolate and are the cornerstone of treatment as per the SLE EULAR gui
Read Article
Links:
Dr. John Cush RheumNow ( View Tweet)
Links:
Dr. John Cush RheumNow ( View Tweet)
Links:
Dr. John Cush RheumNow ( View Tweet)
Janet Pope Janetbirdope ( View Tweet)
Certolizumab Pegol: A Safe And Efficient Treatment In Patients With Uveitis During Pregnancy: Conclusion: CZP seems to be effective and safe in female patients with uveitis during pregnancy and neonates. Abstract AB1055 #EULAR2020 @RheumNow https://t.co/MzeZKBawTg
